CA2987179C - Heterocyclic compounds as inhibitors of vanin-1 enzyme - Google Patents
Heterocyclic compounds as inhibitors of vanin-1 enzyme Download PDFInfo
- Publication number
- CA2987179C CA2987179C CA2987179A CA2987179A CA2987179C CA 2987179 C CA2987179 C CA 2987179C CA 2987179 A CA2987179 A CA 2987179A CA 2987179 A CA2987179 A CA 2987179A CA 2987179 C CA2987179 C CA 2987179C
- Authority
- CA
- Canada
- Prior art keywords
- pyrimidin
- amino
- methanone
- c6alkyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167962P | 2015-05-29 | 2015-05-29 | |
| US62/167,962 | 2015-05-29 | ||
| US201562195005P | 2015-07-21 | 2015-07-21 | |
| US62/195,005 | 2015-07-21 | ||
| PCT/IB2016/052825 WO2016193844A1 (en) | 2015-05-29 | 2016-05-16 | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2987179A1 CA2987179A1 (en) | 2016-12-08 |
| CA2987179C true CA2987179C (en) | 2020-08-25 |
Family
ID=56026933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2987179A Expired - Fee Related CA2987179C (en) | 2015-05-29 | 2016-05-16 | Heterocyclic compounds as inhibitors of vanin-1 enzyme |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10308615B2 (enExample) |
| EP (1) | EP3303303A1 (enExample) |
| JP (1) | JP2018516254A (enExample) |
| CA (1) | CA2987179C (enExample) |
| WO (1) | WO2016193844A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10906888B2 (en) | 2016-07-14 | 2021-02-02 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US10961242B2 (en) * | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
| KR101798840B1 (ko) | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
| AU2018285131B2 (en) * | 2017-06-12 | 2021-11-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
| US11723929B2 (en) | 2017-06-13 | 2023-08-15 | The Regents Of The University Of California | Methods of improving cell-based therapy |
| US10702488B2 (en) * | 2017-12-19 | 2020-07-07 | Theriac Biomedical Inc. | PPAR-γ activators, HDAC inhibitors and their therapeutical usages |
| US11497723B1 (en) * | 2017-12-19 | 2022-11-15 | Tony Antakly | PPAR-gamma activators, HDAC inhibitors and their therapeutical usages |
| WO2019133445A1 (en) * | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
| HUE061186T2 (hu) | 2018-08-28 | 2023-06-28 | Boehringer Ingelheim Int | Heteroaromás vegyületek mint vanin-inhibitorok |
| WO2020102575A1 (en) * | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
| JP7130873B2 (ja) * | 2018-12-03 | 2022-09-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | バニン阻害剤としてのヘテロ芳香族化合物 |
| ES2928919T3 (es) * | 2018-12-03 | 2022-11-23 | Boehringer Ingelheim Int | Compuestos heteroaromáticos como inhibidores de vanina |
| BR112021010823A2 (pt) * | 2018-12-03 | 2021-08-24 | Boehringer Ingelheim International Gmbh | Compostos heteroaromáticos como inibidores de vanina |
| EP4054556A4 (en) * | 2019-11-07 | 2023-11-29 | Increvet, Inc. | SODIUM-GLUCOSE-LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION AND HEART FAILURE IN PETS |
| WO2022081716A1 (en) * | 2020-10-13 | 2022-04-21 | Accubit LLC - Biotechnology | Methods of treating iga nephropathy with thiol-containing molecules |
| US20240124479A1 (en) * | 2020-12-17 | 2024-04-18 | Shanghai Meiyue Biotech Development Co. Ltd | Pyrimidine carboxamide compound and use thereof |
| CN120247898B (zh) * | 2025-03-31 | 2026-07-14 | 大连医科大学附属第二医院 | 一种噻吩甲酰胺类化合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| WO2003072197A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Acc inhibitors |
| EA011086B9 (ru) | 2004-05-12 | 2012-08-30 | Пфайзер Продактс Инк. | Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008065508A1 (en) | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Spiroketone acetyl-coa carboxylase inhibitors |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US8158636B2 (en) * | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
| ES2380408T3 (es) | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| WO2010103437A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| GEP20135907B (en) | 2009-06-05 | 2013-08-12 | Pfizer | L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| TWI525090B (zh) * | 2010-04-27 | 2016-03-11 | Mitsubishi Tanabe Pharma Corp | Novel amide derivatives and their use as pharmaceuticals |
| CA2836474A1 (en) | 2011-05-17 | 2012-11-22 | Plexxikon Inc. | Kinase modulation and indications therefor |
| EP2736329A4 (en) | 2011-07-29 | 2015-03-25 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| WO2013151938A1 (en) | 2012-04-02 | 2013-10-10 | Cytokinetics, Inc. | Methods for improving diaphragm function |
| US9585891B2 (en) | 2012-09-25 | 2017-03-07 | Merck Patent Gmbh | Alpha hydroxy amides |
-
2016
- 2016-05-16 WO PCT/IB2016/052825 patent/WO2016193844A1/en not_active Ceased
- 2016-05-16 JP JP2017561653A patent/JP2018516254A/ja active Pending
- 2016-05-16 EP EP16724127.2A patent/EP3303303A1/en not_active Withdrawn
- 2016-05-16 US US15/574,625 patent/US10308615B2/en active Active
- 2016-05-16 CA CA2987179A patent/CA2987179C/en not_active Expired - Fee Related
-
2019
- 2019-04-10 US US16/380,256 patent/US20190292157A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180148420A1 (en) | 2018-05-31 |
| JP2018516254A (ja) | 2018-06-21 |
| EP3303303A1 (en) | 2018-04-11 |
| CA2987179A1 (en) | 2016-12-08 |
| WO2016193844A1 (en) | 2016-12-08 |
| US10308615B2 (en) | 2019-06-04 |
| US20190292157A1 (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10308615B2 (en) | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | |
| CA2697081C (en) | 5-(4-(haloalkoxy)phenyl)pyrimidine-2-amine compounds and compositions as kinase inhibitors | |
| US10155765B2 (en) | Carboxamide inhibitors of IRAK4 activity | |
| US10906888B2 (en) | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | |
| CN119768409A (zh) | K-Ras突变蛋白抑制剂 | |
| AU2012335220B2 (en) | 2-thiopyrimidinones | |
| JP2018527337A (ja) | 二環式縮合ヘテロアリールまたはアリール化合物 | |
| US20130150354A1 (en) | New selective ccr2 antagonists | |
| US20180170906A1 (en) | Therapeutic inhibitory compounds | |
| WO2012143415A1 (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | |
| MXPA06003557A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
| WO2019133445A1 (en) | Aminothiazoles as inhibitors of vanin-1 | |
| CN105121443A (zh) | 蛋白激酶抑制剂 | |
| WO2013010839A1 (en) | Novel and selective ccr2 antagonists | |
| US20130090338A1 (en) | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments | |
| CN110997657A (zh) | 咪唑烷化合物 | |
| US20160368919A1 (en) | Novel pyridine pyrazinones as bet-family bromodomain inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171124 |
|
| MKLA | Lapsed |
Effective date: 20210517 |